Upstream Bio matches first funding round with another $200M to get asthma drug to PhIII
08 Jun 2023
Phase 2
Upstream Bio has raised another $200 million to go through Phase II studies and prepare for late-stage trials of an ex-Astellas monoclonal antibody in anticipation of competition with AstraZeneca and Amgen’s asthma drug Tezspire.
The raise, disclosed Thursday morning, mirrors its first funding round from 2021 that bankrolled the Waltham, MA-based startup’s ongoing Phase Ib in asthma. It plans to use the new round to support mid-stage studies in both asthma and chronic rhinosinusitis with nasal polyps. Both of those studies will kick off in the first quarter of 2024, CEO Samantha Truex told Endpoints News.
Preview
Source: EndPoints
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters
SIGN UP
LOG IN
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-Drugs
Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.